Modificare „ATRECA INC TECH CODE”

Pagina dedicata companiei ATRECA INC TECH CODE listata cu simbolul US.BCEL

==Descriere companie==
Atreca, Inc. (www.atreca.com) is a clinical-stage biopharmaceutical company. The Company use its platform to discover and develop antibody-based immunotherapeutic to treat a range of solid tumor types. The Company's lead product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. Its platform enables it to interrogate an active B cell response within an individual cancer patient to identify antibody-target pairs, which enable them to develop antibody-based product candidates to treat patients with solid tumors. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. APN-122597 is its other product candidate. The Company's Immune Repertoire Capture (IRC) technology generates natively paired heavy and light chain sequences of the antibodies expressed by single B cells isolated from patient samples.

==Grafic actiuni companie==
<iframe key="tradeville" path="graficSimbol/US.BCEL" />

==Ultimele stiri despre ATRECA INC TECH CODE (US.BCEL)==
<dynamicpagelist>
category=US.BCEL
count=10
order=descending
addfirstcategorydate=false
</dynamicpagelist>

[[Categorie:US.BCEL]][[Categorie:Stiri despre companii]]